Healthcare / BiotechnologyNasdaqGS
$10.28
-0.23 (-2.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-69.0M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$93M
P/E
N/A
•EV/EBITDA
2.0x
↓ROE
-84.9%
↓Gross Margin
82.4%
↑Debt/Equity
-0.27
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-42.2%
FCF / Net income
-1.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $120.8M · net income $32.7M · FCF $-50.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $120.8M | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — | — | — | — | — | — | — |
| Net Income | $32.7M | $32.7M | $-85.4M | $-276.1M | $-228.3M | $-340.1M | $-306.6M | $-291.0M | $-230.7M | $-119.5M | $-79.0M | $-57.2M | $-28.0M | $-8.8M |
| EBITDA | $38.6M | $38.6M | $-75.7M | $-266.0M | $-222.3M | $-331.1M | $-300.7M | $-288.6M | $-233.4M | $-120.6M | $-80.9M | $-58.4M | — | — |
| EPS | — | — | -11.41 | -65.19 | -56.00 | -90.75 | -103.75 | — | — | — | — | — | — | — |
| Gross Margin | 82.4% | 82.4% | 83.7% | -3.7% | 100.0% | — | — | — | — | — | — | — | — | — |
| Operating Margin | 29.7% | 29.7% | -64.7% | -3219.5% | -441.2% | — | — | — | — | — | — | — | — | — |
| Net Margin | 27.1% | 27.1% | -66.2% | -3220.9% | -359.1% | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | -0.27 | -0.27 | -0.45 | -0.58 | 0.57 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.16 | 2.16 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-50.9M | $-50.9M | $-69.0M | $-194.2M | $-274.6M | $-231.1M | $-185.3M | $-241.4M | $-215.7M | $-107.7M | $-63.0M | — | — | — |
| Returns | ||||||||||||||
| ROE | -84.9% | -84.9% | 87.8% | 278.3% | -180.3% | -121.6% | -66.3% | -100.1% | -68.0% | -67.2% | -31.2% | -18.2% | -27.1% | 79.6% |
| Valuation | ||||||||||||||
| EV/EBITDA | 2.00 | 2.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | — | — | — | — | 2.82 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -6.3% | -6.3% | 1404.0% | -86.5% | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | — | — | 82.5% | -16.4% | — | 12.5% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-11.41 → n/d
Residual
+31.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.